Bibliografie

Medizinische Berichte & Studien:

  1. Moruisi KG, Oosthuizen W, Opperman AM.
    Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis.
    J Am Coll Nutr. 2006 Feb;25(1):41-8.
  2. Comparison of efficacy of plant stanol ester and sterol ester: short-term and longer-term studies.
    O'Neill FH et al.
    Am J Cardiol. 2005 Jul 4;96(1A):29D-36D.
  3. Non-nutritive bioactive constituents of plants: phytosterols.
    Miettinen TA, Gylling H.
    Int J Vitam Nutr Res. 2003 Mar;73(2):127-34.
  4. Plant sterols and their derivatives: the current spread of results.
    Jones PJ, Raeini-Sarjaz M.
    Nutr Rev 2001 Jan;59(1 Pt 1):21-4
  5. Monograph. Plant sterols and sterolins.
    Altern Med Rev 2001 Apr;6(2):203-6
  6. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up.
    Berges RR, Kassen A, Senge T
    BJU Int 2000 May;85(7):842-6
  7. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis: clinical and experimental evidence.
    Moghadasian MH, Frohlich JJ
    Am J Med 1999 Dec;107(6):588-94
  8. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.
    Berges RR, Windeler J, Trampisch HJ, Senge T
    Lancet 1995 Jun 17;345(8964):1529-32
  9. beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review.
    Wilt TJ, MacDonald R, Ishani A
    BJU Int 1999 Jun;83(9):976-83
  10. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
    Klippel KF, Hiltl DM, Schipp B
    Br J Urol 1997 Sep;80(3):427-32

(References searched and cited from National Library of Medicine-PubMed at http://www.ncbi.nlm.nih.gov/PubMed/ )

Angaben des Herstellers:

Description

Although plant sterols (phytosterols) and cholesterol have similar chemical structures, they differ markedly in their synthesis, intestinal absorption, and metabolic fate. Phytosterols inhibit intestinal cholesterol absorption, thereby lowering plasma total and low-density lipoprotein (LDL) cholesterol levels.
Phytosterols, abundant in fat-soluble fractions of plants, are easily destroyed when food is produced industrially.
SITOSAN contains beta-sitosterol in abundance.
SITOSAN might be a useful hypolipidemic agent for the treatment of mild hypercholesterolemia.
Daily dosage (6 tablets) contains 1620 mg of beta-sitosterol.
Main Ingredients of SITOSAN:
beta-Sitosterol preparation (min. 90% beta-sitosterol).......60 %
Pectin.......................................................10 %
Corn Starch...................................................3 %
E460, E551, E572
Dosage:
3 tablets 2 times a day.
Package:
90 tablets / 45 g
KOLESTOP® containing beta-sitosterol and beta-sitostanol mixture is also available.
Usage

Studies show dietary phytosterols reduce serum cholesterol by inhibiting cholesterol absorption and are effective in lowering serum total cholesterol and LDL cholesterol in subjects with mild hypercholesterolemia.
A natural way to avoid risks caused by high cholesterol values.
Addition to diet of the phytosterol represents an effective means of improving circulating lipid profiles to reduce risk of coronary heart disease.
Significant improvement in urological symptoms and urinary flow parameters also show the effectiveness of beta-sitosterol in the treatment of benign prostatic hyperplasia. Recent clinical trial has shown that in the treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol, beneficial effects of beta-sitosterol treatment recorded in the 6-month double-blind trial were maintained for 18 months.